You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDihydroergotamine
Accession NumberDB00320  (APRD00476)
TypeSmall Molecule
GroupsApproved
DescriptionA 9,10alpha-dihydro derivative of ergotamine. It is used as a vasoconstrictor, specifically for the therapy of migraine disorders. [PubChem]
Structure
Thumb
Synonyms
(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman
9,10-dihydro-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione
9,10-dihydroergotamine
Dihidroergotamina
Dihydroergotamin
Dihydroergotamine
Dihydroergotaminum
Diidroergotamina
External Identifiers
  • MAP-0004
  • MAP0004
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
D.H.E. 45Injection, solution1 mg/mLIntramuscular; Intravenous; SubcutaneousValeant Pharmaceuticals North America2001-10-03Not applicableUs
Dihydroergotamine (dhe), 1mg/mlLiquid1 mgIntramuscular; Intravenous; SubcutaneousSterimax Inc1946-12-31Not applicableCanada
Dihydroergotamine MesylateSpray4 mg/mLNasalOceanside Pharmaceuticals2013-03-18Not applicableUs
Dihydroergotamine Mesylate Injection USPLiquid1 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1999-12-23Not applicableCanada
MigranalSpray4 mg/mLNasalValeant Pharmaceuticals North America LLC1997-12-08Not applicableUs
Migranal Nasal Spray 4mg/mlLiquid4 mgNasalSterimax Inc1996-11-05Not applicableCanada
PMS-dihydroergotamineLiquid4 mgNasalPharmascience IncNot applicableNot applicableCanada
PMS-dihydroergotamineLiquid1 mgIntramuscular; Intravenous; SubcutaneousPharmascience IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dihydroergotamine MesylateInjection, solution1 mg/mLIntramuscular; Intravenous; SubcutaneousPaddock Laboratories, LLC2003-04-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DihydergotSandoz
ErgontSigmapharm
ErgotoninNot Available
IkaranPierre Fabre
OrstanormAmdipharm
VerladynVerla
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dihydroergotamine mesylate
6190-39-2
Thumb
  • InChI Key: ADYPXRFPBQGGAH-UMYZUSPBSA-N
  • Monoisotopic Mass: 679.267584474
  • Average Mass: 679.79
DBSALT000997
Dihydroergotamine tartrate
5989-77-5
Thumb
  • InChI Key: FXDJFTCVYTUARH-YZPGULDNSA-N
  • Monoisotopic Mass: 2483.134315159
  • Average Mass: 2484.842
DBSALT001066
Categories
UNII436O5HM03C
CAS number511-12-6
WeightAverage: 583.6774
Monoisotopic: 583.279469319
Chemical FormulaC33H37N5O5
InChI KeyLUZRJRNZXALNLM-JGRZULCMSA-N
InChI
InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
IUPAC Name
(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
SMILES
[H][C@@]12CCCN1C(=O)[[email protected]](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[[email protected]]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Pharmacology
IndicationFor the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
Structured Indications
PharmacodynamicsDihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT1Da and 5-HT1Db receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors.
Mechanism of actionTwo theories have been proposed to explain the efficacy of 5-HT1D receptor agonists in migraine: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 1DProteinyes
agonist
HumanP28221 details
5-hydroxytryptamine receptor 1BProteinyes
agonist
HumanP28222 details
Alpha-2A adrenergic receptorProteinunknown
agonist
HumanP08913 details
5-hydroxytryptamine receptor 2BProteinunknown
agonist
HumanP41595 details
Related Articles
AbsorptionInterpatient variable and may be dependent on the administration technique
Volume of distribution
  • 800 L
Protein binding93% (to plasma proteins)
Metabolism

Hepatic

Route of eliminationThe major excretory route of dihydroergotamine is via the bile in the feces. Only 6%-7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection.
Half life9 hours
Clearance
  • 1.5 L/min
ToxicitySide effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Dihydroergotamine can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Dihydroergotamine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Dihydroergotamine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe metabolism of Dihydroergotamine can be decreased when combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Dihydroergotamine.Approved
AcebutololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Dihydroergotamine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Dihydroergotamine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Dihydroergotamine.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Dihydroergotamine.Approved
AdrafinilDihydroergotamine may increase the hypertensive activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dihydroergotamine.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Dihydroergotamine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Dihydroergotamine.Experimental
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Dihydroergotamine.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Dihydroergotamine.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Dihydroergotamine.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Dihydroergotamine.Approved
AlmotriptanDihydroergotamine may increase the vasoconstricting activities of Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Dihydroergotamine can be increased when it is combined with Alogliptin.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Dihydroergotamine.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Dihydroergotamine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Dihydroergotamine.Approved, Illicit, Investigational
AlprenololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Dihydroergotamine.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Dihydroergotamine.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Dihydroergotamine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Dihydroergotamine.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Dihydroergotamine.Approved
AmiodaroneThe metabolism of Dihydroergotamine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amisulpride.Approved, Investigational
AmitrazDihydroergotamine may increase the hypertensive activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Dihydroergotamine.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Dihydroergotamine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Amprenavir.Approved
AnisodamineDihydroergotamine may increase the hypertensive activities of Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Dihydroergotamine.Approved
Antithrombin III humanThe serum concentration of Dihydroergotamine can be increased when it is combined with Antithrombin III human.Approved
Aop200704Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Dihydroergotamine.Approved
ApomorphineDihydroergotamine may increase the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineDihydroergotamine may increase the hypertensive activities of Apraclonidine.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Dihydroergotamine.Approved, Investigational
AprepitantThe serum concentration of Dihydroergotamine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Dihydroergotamine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineDihydroergotamine may increase the hypertensive activities of Arbutamine.Approved
ArformoterolDihydroergotamine may increase the hypertensive activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Dihydroergotamine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Dihydroergotamine.Approved, Investigational
ArotinololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Dihydroergotamine.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Dihydroergotamine.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Dihydroergotamine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Dihydroergotamine.Approved, Withdrawn
AsunaprevirThe serum concentration of Dihydroergotamine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineThe metabolism of Dihydroergotamine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Dihydroergotamine.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Dihydroergotamine.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Dihydroergotamine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Azaperone.Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Dihydroergotamine.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Dihydroergotamine.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Dihydroergotamine.Investigational
BatimastatThe serum concentration of Dihydroergotamine can be increased when it is combined with Batimastat.Experimental
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Dihydroergotamine.Approved
BefunololDihydroergotamine may increase the hypertensive activities of Befunolol.Experimental
BenazeprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinThe metabolism of Dihydroergotamine can be decreased when combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Dihydroergotamine can be increased when it is combined with Benzamidine.Experimental
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Dihydroergotamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Dihydroergotamine.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Dihydroergotamine.Approved, Vet Approved
BetaxololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BexaroteneThe serum concentration of Dihydroergotamine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Dihydroergotamine.Approved
Bi201335The serum concentration of Dihydroergotamine can be increased when it is combined with Bi201335.Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Dihydroergotamine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Bifeprunox.Investigational
BisoprololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BitolterolDihydroergotamine may increase the hypertensive activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Dihydroergotamine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Dihydroergotamine can be increased when it is combined with Boceprevir.Approved
BopindololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Dihydroergotamine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Dihydroergotamine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dihydroergotamine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dihydroergotamine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Dihydroergotamine.Approved
BrimonidineDihydroergotamine may increase the hypertensive activities of Brimonidine.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Dihydroergotamine.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Dihydroergotamine.Approved, Illicit
BromocriptineDihydroergotamine may increase the vasoconstricting activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Dihydroergotamine.Approved
BucindololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Dihydroergotamine.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Dihydroergotamine.Approved
BufuralolDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Dihydroergotamine.Approved, Investigational
BupranololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Dihydroergotamine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Dihydroergotamine.Approved
BuspironeThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Buspirone.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Dihydroergotamine.Approved, Investigational
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Dihydroergotamine.Approved
CabergolineCabergoline may increase the vasoconstricting activities of Dihydroergotamine.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Dihydroergotamine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Dihydroergotamine.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Dihydroergotamine.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Dihydroergotamine.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Dihydroergotamine.Approved
CandoxatrilThe serum concentration of Dihydroergotamine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Dihydroergotamine can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Dihydroergotamine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Dihydroergotamine.Approved
CarbomycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Dihydroergotamine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Dihydroergotamine.Approved
CaroxazoneThe metabolism of Dihydroergotamine can be decreased when combined with Caroxazone.Withdrawn
CarteololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Dihydroergotamine.Approved, Investigational
CeliprololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
CeritinibThe serum concentration of Dihydroergotamine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Dihydroergotamine.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Dihydroergotamine.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Dihydroergotamine.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Dihydroergotamine.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Dihydroergotamine.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Dihydroergotamine.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Dihydroergotamine.Approved, Nutraceutical
ChymostatinThe serum concentration of Dihydroergotamine can be increased when it is combined with Chymostatin.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Dihydroergotamine.Approved, Investigational
CilastatinThe serum concentration of Dihydroergotamine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Dihydroergotamine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Dihydroergotamine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Dihydroergotamine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
CirazolineDihydroergotamine may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe metabolism of Cisapride can be decreased when combined with Dihydroergotamine.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Dihydroergotamine.Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Dihydroergotamine.Approved
ClarithromycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Dihydroergotamine can be decreased when combined with Clemastine.Approved
ClenbuterolDihydroergotamine may increase the hypertensive activities of Clenbuterol.Approved, Vet Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Dihydroergotamine.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Dihydroergotamine.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Dihydroergotamine.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Dihydroergotamine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Dihydroergotamine.Approved, Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Dihydroergotamine.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Dihydroergotamine.Approved, Illicit
ClonidineDihydroergotamine may increase the hypertensive activities of Clonidine.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Dihydroergotamine.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Dihydroergotamine.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Dihydroergotamine.Approved, Illicit
ClotrimazoleThe metabolism of Dihydroergotamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Dihydroergotamine.Approved
CobicistatThe serum concentration of Dihydroergotamine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Dihydroergotamine.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Dihydroergotamine.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Dihydroergotamine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dihydroergotamine.Approved
ConivaptanThe serum concentration of Dihydroergotamine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Dihydroergotamine.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Dihydroergotamine.Approved
CrizotinibThe serum concentration of Dihydroergotamine can be increased when it is combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Dihydroergotamine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Dihydroergotamine.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Dihydroergotamine.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Dihydroergotamine.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dihydroergotamine.Approved
DabrafenibThe serum concentration of Dihydroergotamine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Dihydroergotamine.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Dihydroergotamine.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Dihydroergotamine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Dihydroergotamine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Dihydroergotamine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Dihydroergotamine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Dihydroergotamine.Approved, Investigational
DarunavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Dihydroergotamine.Approved
DasatinibThe serum concentration of Dihydroergotamine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Dihydroergotamine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Dihydroergotamine.Approved
DeferasiroxThe serum concentration of Dihydroergotamine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Dihydroergotamine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Dihydroergotamine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Desvenlafaxine.Approved
DetomidineDihydroergotamine may increase the hypertensive activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dihydroergotamine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineDihydroergotamine may increase the hypertensive activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dextromethorphan.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Dihydroergotamine.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Dihydroergotamine.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dihydroergotamine.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Dihydroergotamine.Approved
DigoxinThe metabolism of Digoxin can be decreased when combined with Dihydroergotamine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Dihydroergotamine.Approved, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Dihydroergotamine.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Dihydroergotamine.Approved
DipivefrinDihydroergotamine may increase the hypertensive activities of Dipivefrin.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Dihydroergotamine.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Dihydroergotamine.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Dihydroergotamine.Approved
DobutamineDihydroergotamine may increase the hypertensive activities of Dobutamine.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Dihydroergotamine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Dihydroergotamine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Dihydroergotamine.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Dihydroergotamine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Dihydroergotamine.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Dihydroergotamine.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Dihydroergotamine.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Dihydroergotamine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Dihydroergotamine.Approved, Investigational
DoxycyclineThe metabolism of Dihydroergotamine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Dihydroergotamine.Approved, Illicit
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Dihydroergotamine.Approved
DroperidolThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Droperidol.Approved, Vet Approved
DroxidopaDihydroergotamine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Dihydroergotamine.Approved, Investigational
EcabetThe serum concentration of Dihydroergotamine can be increased when it is combined with Ecabet.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Dihydroergotamine.Approved
EfavirenzThe serum concentration of Dihydroergotamine can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Dihydroergotamine can be increased when it is combined with Elafin.Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Dihydroergotamine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Dihydroergotamine.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Dihydroergotamine.Approved
EnalaprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Dihydroergotamine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Dihydroergotamine can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Dihydroergotamine can be decreased when it is combined with Enzalutamide.Approved
EphedrineDihydroergotamine may increase the hypertensive activities of Ephedrine.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Dihydroergotamine.Approved, Investigational
EpinephrineDihydroergotamine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Dihydroergotamine.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Dihydroergotamine.Approved, Nutraceutical
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Dihydroergotamine.Approved
ErgonovineErgonovine may increase the vasoconstricting activities of Dihydroergotamine.Approved
ErgotamineDihydroergotamine may increase the hypertensive activities of Ergotamine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Dihydroergotamine.Approved, Investigational
ErythromycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Dihydroergotamine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Dihydroergotamine.Investigational
EsmololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Dihydroergotamine.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Dihydroergotamine.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Dihydroergotamine.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Dihydroergotamine.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Dihydroergotamine.Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Dihydroergotamine.Approved, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Dihydroergotamine.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Dihydroergotamine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Dihydroergotamine.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Dihydroergotamine.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Dihydroergotamine.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Dihydroergotamine.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Dihydroergotamine.Approved, Illicit
EtilefrineDihydroergotamine may increase the hypertensive activities of Etilefrine.Withdrawn
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Dihydroergotamine.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Dihydroergotamine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Dihydroergotamine.Approved, Investigational
EtravirineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dihydroergotamine.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Dihydroergotamine.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Dihydroergotamine.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Dihydroergotamine.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Dihydroergotamine.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Dihydroergotamine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Dihydroergotamine.Approved
FenoterolDihydroergotamine may increase the hypertensive activities of Fenoterol.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Dihydroergotamine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Dihydroergotamine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Dihydroergotamine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Dihydroergotamine.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Dihydroergotamine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Dihydroergotamine.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Dihydroergotamine.Approved
FluconazoleThe metabolism of Dihydroergotamine can be decreased when combined with Fluconazole.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Dihydroergotamine.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Dihydroergotamine.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Dihydroergotamine.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluphenazine.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Dihydroergotamine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluspirilene.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Dihydroergotamine.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Dihydroergotamine.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Dihydroergotamine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Dihydroergotamine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydroergotamine.Approved, Investigational
FormoterolDihydroergotamine may increase the hypertensive activities of Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dihydroergotamine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Dihydroergotamine can be increased when combined with Fosphenytoin.Approved
FrovatriptanDihydroergotamine may increase the vasoconstricting activities of Frovatriptan.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Dihydroergotamine.Approved, Investigational
FurazolidoneThe metabolism of Dihydroergotamine can be decreased when combined with Furazolidone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dihydroergotamine can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Dihydroergotamine can be increased when it is combined with Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Dihydroergotamine.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Dihydroergotamine.Approved, Investigational
GeldanamycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Dihydroergotamine.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Dihydroergotamine.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Dihydroergotamine.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Dihydroergotamine.Approved
GM6001The serum concentration of Dihydroergotamine can be increased when it is combined with GM6001.Experimental
GranisetronThe metabolism of Granisetron can be decreased when combined with Dihydroergotamine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Dihydroergotamine.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Dihydroergotamine.Withdrawn
GuanabenzDihydroergotamine may increase the hypertensive activities of Guanabenz.Approved
GuanfacineDihydroergotamine may increase the hypertensive activities of Guanfacine.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Dihydroergotamine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Dihydroergotamine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Dihydroergotamine.Approved
HexoprenalineDihydroergotamine may increase the hypertensive activities of Hexoprenaline.Approved, Withdrawn
HigenamineDihydroergotamine may increase the hypertensive activities of Higenamine.Investigational
HirulogThe serum concentration of Dihydroergotamine can be increased when it is combined with Hirulog.Experimental
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Dihydroergotamine.Approved
HydracarbazineThe metabolism of Dihydroergotamine can be decreased when combined with Hydracarbazine.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Dihydroergotamine.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Dihydroergotamine.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Dihydroergotamine.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Dihydroergotamine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Dihydroergotamine.Approved
IdelalisibThe serum concentration of Dihydroergotamine can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Dihydroergotamine can be increased when it is combined with idraparinux.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dihydroergotamine resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Dihydroergotamine.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Dihydroergotamine.Approved
ImidaprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Dihydroergotamine.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Dihydroergotamine.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Dihydroergotamine.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Dihydroergotamine.Approved
IndenololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Dihydroergotamine.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Dihydroergotamine.Approved
IproclozideThe metabolism of Dihydroergotamine can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Dihydroergotamine can be decreased when combined with Iproniazid.Withdrawn
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Dihydroergotamine.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Dihydroergotamine.Approved, Investigational
IsocarboxazidThe metabolism of Dihydroergotamine can be decreased when combined with Isocarboxazid.Approved
IsoetarineDihydroergotamine may increase the hypertensive activities of Isoetarine.Approved
IsoflurophateThe serum concentration of Dihydroergotamine can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoprenalineDihydroergotamine may increase the hypertensive activities of Isoprenaline.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Dihydroergotamine.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Dihydroergotamine.Approved
IsoxsuprineDihydroergotamine may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Dihydroergotamine can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Dihydroergotamine can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Dihydroergotamine.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Dihydroergotamine.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Dihydroergotamine.Approved, Investigational
IxazomibThe serum concentration of Dihydroergotamine can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Josamycin.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Dihydroergotamine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Dihydroergotamine.Approved
KetoconazoleThe serum concentration of Dihydroergotamine can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Dihydroergotamine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Kitasamycin.Experimental
LabetalolDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Dihydroergotamine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Dihydroergotamine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Dihydroergotamine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Dihydroergotamine.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Dihydroergotamine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dihydroergotamine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Dihydroergotamine.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Dihydroergotamine.Approved
LepirudinThe serum concentration of Dihydroergotamine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Dihydroergotamine.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Dihydroergotamine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Dihydroergotamine.Approved, Investigational
LevobunololLevobunolol may increase the vasoconstricting activities of Dihydroergotamine.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Dihydroergotamine.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Dihydroergotamine.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Dihydroergotamine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Levomilnacipran.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Dihydroergotamine.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Dihydroergotamine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
LinagliptinThe serum concentration of Dihydroergotamine can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Linezolid.Approved, Investigational
LisinoprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideDihydroergotamine may increase the vasoconstricting activities of Lisuride.Approved
LithiumThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lithium.Approved
LofexidineDihydroergotamine may increase the hypertensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Dihydroergotamine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Dihydroergotamine.Approved
LopinavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Dihydroergotamine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Dihydroergotamine.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Dihydroergotamine.Approved
LovastatinThe metabolism of Dihydroergotamine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Loxapine.Approved
Lu AA21004Dihydroergotamine may increase the vasoconstricting activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Dihydroergotamine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Dihydroergotamine can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Dihydroergotamine.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Dihydroergotamine.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Dihydroergotamine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Dihydroergotamine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Maprotiline.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Dihydroergotamine.Approved, Investigational
MebanazineThe metabolism of Dihydroergotamine can be decreased when combined with Mebanazine.Withdrawn
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
MedetomidineDihydroergotamine may increase the hypertensive activities of Medetomidine.Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Dihydroergotamine.Approved, Investigational
MefloquineThe metabolism of Mefloquine can be decreased when combined with Dihydroergotamine.Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Melperone.Approved
MephentermineDihydroergotamine may increase the hypertensive activities of Mephentermine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mesoridazine.Approved
MetaraminolDihydroergotamine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methadone.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Dihydroergotamine.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dihydroergotamine.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methotrimeprazine.Approved
MethoxamineDihydroergotamine may increase the hypertensive activities of Methoxamine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Dihydroergotamine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
MethyldopaDihydroergotamine may increase the hypertensive activities of Methyldopa.Approved
Methylene blueThe metabolism of Dihydroergotamine can be decreased when combined with Methylene blue.Investigational
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Dihydroergotamine.Approved
MetipranololMetipranolol may increase the vasoconstricting activities of Dihydroergotamine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Metoclopramide.Approved, Investigational
MetoprololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Dihydroergotamine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Dihydroergotamine.Approved
MianserinThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Mianserin.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Dihydroergotamine.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Dihydroergotamine.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Dihydroergotamine.Approved, Illicit
MidodrineDihydroergotamine may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe serum concentration of Dihydroergotamine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Milnacipran.Approved
MinaprineThe metabolism of Dihydroergotamine can be decreased when combined with Minaprine.Approved
MirabegronDihydroergotamine may increase the hypertensive activities of Mirabegron.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Dihydroergotamine.Approved
MitotaneThe serum concentration of Dihydroergotamine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Dihydroergotamine.Approved, Investigational
MoclobemideThe metabolism of Dihydroergotamine can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Dihydroergotamine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Molindone.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Dihydroergotamine.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Dihydroergotamine.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Dihydroergotamine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Dihydroergotamine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NafamostatThe serum concentration of Dihydroergotamine can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Dihydroergotamine can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dihydroergotamine.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
NaphazolineDihydroergotamine may increase the hypertensive activities of Naphazoline.Approved
NaratriptanDihydroergotamine may increase the vasoconstricting activities of Naratriptan.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Dihydroergotamine.Approved, Investigational
NCX 4016The serum concentration of Dihydroergotamine can be increased when it is combined with NCX 4016.Investigational
NebivololDihydroergotamine may increase the hypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Dihydroergotamine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dihydroergotamine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Dihydroergotamine can be increased when combined with Nevirapine.Approved
NialamideThe metabolism of Dihydroergotamine can be decreased when combined with Nialamide.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Dihydroergotamine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Dihydroergotamine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Dihydroergotamine.Approved
NilotinibThe metabolism of Nilotinib can be decreased when combined with Dihydroergotamine.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Dihydroergotamine.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Dihydroergotamine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dihydroergotamine.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Dihydroergotamine.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Dihydroergotamine.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Dihydroergotamine.Approved
NitroaspirinThe serum concentration of Dihydroergotamine can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinDihydroergotamine may decrease the vasodilatory activities of Nitroglycerin.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Dihydroergotamine.Approved
NorepinephrineDihydroergotamine may increase the hypertensive activities of Norepinephrine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Dihydroergotamine.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Dihydroergotamine.Approved
NortriptylineNortriptyline may decrease the antihypertensive activities of Dihydroergotamine.Approved
NylidrinDihydroergotamine may increase the hypertensive activities of Nylidrin.Approved
OctamoxinThe metabolism of Dihydroergotamine can be decreased when combined with Octamoxin.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Dihydroergotamine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Dihydroergotamine.Approved
OleandomycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Oleandomycin.Vet Approved
OlodaterolDihydroergotamine may increase the hypertensive activities of Olodaterol.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Dihydroergotamine.Approved
OmapatrilatThe serum concentration of Dihydroergotamine can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Dihydroergotamine.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Dihydroergotamine.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Dihydroergotamine.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Dihydroergotamine.Investigational
OrciprenalineDihydroergotamine may increase the hypertensive activities of Orciprenaline.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Dihydroergotamine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Dihydroergotamine can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Dihydroergotamine.Approved
OtamixabanThe serum concentration of Dihydroergotamine can be increased when it is combined with Otamixaban.Investigational
OxazepamThe metabolism of Oxazepam can be decreased when combined with Dihydroergotamine.Approved
OxprenololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Dihydroergotamine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineDihydroergotamine may increase the hypertensive activities of Oxymetazoline.Approved
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Dihydroergotamine.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
PalbociclibThe serum concentration of Dihydroergotamine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Dihydroergotamine.Approved, Investigational
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Dihydroergotamine.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Dihydroergotamine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Dihydroergotamine.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Dihydroergotamine.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Dihydroergotamine.Approved
PargylineThe metabolism of Dihydroergotamine can be decreased when combined with Pargyline.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Dihydroergotamine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dihydroergotamine.Approved
PenbutololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Dihydroergotamine.Approved
PentobarbitalThe metabolism of Dihydroergotamine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Dihydroergotamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Perazine.Investigational
PergolideDihydroergotamine may increase the vasoconstricting activities of Pergolide.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Dihydroergotamine.Approved
PerindoprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Dihydroergotamine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Dihydroergotamine.Approved
PethidineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Dihydroergotamine.Withdrawn
PhenelzineThe metabolism of Dihydroergotamine can be decreased when combined with Phenelzine.Approved
PheniprazineThe metabolism of Dihydroergotamine can be decreased when combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Dihydroergotamine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Dihydroergotamine.Approved
PhenoxypropazineThe metabolism of Dihydroergotamine can be decreased when combined with Phenoxypropazine.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Dihydroergotamine.Approved
PhenylephrineDihydroergotamine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineDihydroergotamine may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Dihydroergotamine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Dihydroergotamine can be increased when it is combined with Phosphoramidon.Experimental
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Dihydroergotamine.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Dihydroergotamine.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Dihydroergotamine.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Dihydroergotamine.Withdrawn
PindololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Dihydroergotamine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pipamperone.Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Dihydroergotamine.Approved
PirbuterolDihydroergotamine may increase the hypertensive activities of Pirbuterol.Approved
PirlindoleThe metabolism of Dihydroergotamine can be decreased when combined with Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Dihydroergotamine.Approved
PivhydrazineThe metabolism of Dihydroergotamine can be decreased when combined with Pivhydrazine.Withdrawn
PodofiloxThe metabolism of Podofilox can be decreased when combined with Dihydroergotamine.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Dihydroergotamine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Dihydroergotamine.Approved
PosaconazoleThe serum concentration of Dihydroergotamine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Dihydroergotamine.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Dihydroergotamine.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Dihydroergotamine.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Dihydroergotamine.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Dihydroergotamine.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Dihydroergotamine.Approved
PrimidoneThe metabolism of Dihydroergotamine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Dihydroergotamine can be increased when it is combined with Prinomastat.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Procarbazine.Approved
ProcaterolDihydroergotamine may increase the hypertensive activities of Procaterol.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Dihydroergotamine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Promethazine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Dihydroergotamine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Propericiazine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Dihydroergotamine.Approved, Investigational, Vet Approved
PropranololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prothipendyl.Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Dihydroergotamine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dihydroergotamine.Approved
PRX-00023Dihydroergotamine may increase the vasoconstricting activities of PRX-00023.Investigational
PseudoephedrineDihydroergotamine may increase the hypertensive activities of Pseudoephedrine.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Dihydroergotamine.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Dihydroergotamine.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Dihydroergotamine.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Dihydroergotamine.Approved
QuinaprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Dihydroergotamine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Dihydroergotamine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Dihydroergotamine.Approved, Investigational
RacecadotrilThe serum concentration of Dihydroergotamine can be increased when it is combined with Racecadotril.Investigational
RacepinephrineDihydroergotamine may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Raclopride.Investigational
RactopamineDihydroergotamine may increase the hypertensive activities of Ractopamine.Vet Approved
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Dihydroergotamine.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Dihydroergotamine.Approved, Investigational
RamiprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Dihydroergotamine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dihydroergotamine.Approved, Investigational
RasagilineThe metabolism of Dihydroergotamine can be decreased when combined with Rasagiline.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Dihydroergotamine.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Dihydroergotamine.Approved
RemikirenThe serum concentration of Dihydroergotamine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Dihydroergotamine.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Dihydroergotamine.Approved
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Dihydroergotamine.Approved
RifabutinThe metabolism of Dihydroergotamine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Dihydroergotamine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Dihydroergotamine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
RilmenidineDihydroergotamine may increase the hypertensive activities of Rilmenidine.Investigational
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Dihydroergotamine.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Dihydroergotamine.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Dihydroergotamine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Dihydroergotamine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ritanserin.Investigational
RitobegronDihydroergotamine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineDihydroergotamine may increase the hypertensive activities of Ritodrine.Approved
RitonavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Dihydroergotamine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanDihydroergotamine may increase the vasoconstricting activities of Rizatriptan.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Dihydroergotamine.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Dihydroergotamine.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Dihydroergotamine.Approved, Investigational
RomifidineDihydroergotamine may increase the hypertensive activities of Romifidine.Vet Approved
RopiniroleDihydroergotamine may increase the vasoconstricting activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Dihydroergotamine.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Dihydroergotamine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Dihydroergotamine.Approved
RoxithromycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Roxithromycin.Approved, Withdrawn
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Dihydroergotamine.Approved
SafrazineThe metabolism of Dihydroergotamine can be decreased when combined with Safrazine.Withdrawn
SalbutamolDihydroergotamine may increase the hypertensive activities of Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Dihydroergotamine.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Dihydroergotamine.Approved
SaquinavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Dihydroergotamine.Approved
SelegilineThe metabolism of Dihydroergotamine can be decreased when combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Dihydroergotamine.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Dihydroergotamine.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Dihydroergotamine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sertraline.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Dihydroergotamine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be decreased when combined with Dihydroergotamine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dihydroergotamine.Approved
SiltuximabThe serum concentration of Dihydroergotamine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Dihydroergotamine.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Dihydroergotamine.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Dihydroergotamine.Approved, Investigational
SitagliptinThe serum concentration of Dihydroergotamine can be increased when it is combined with Sitagliptin.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Dihydroergotamine.Approved
SolabegronDihydroergotamine may increase the hypertensive activities of Solabegron.Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Dihydroergotamine.Approved
SolithromycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Solithromycin.Investigational
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Dihydroergotamine.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Dihydroergotamine.Approved, Investigational
SotalolDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Dihydroergotamine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Dihydroergotamine.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Dihydroergotamine.Approved
SpiraprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Spirapril.Approved
SR 58611Dihydroergotamine may increase the hypertensive activities of SR 58611.Investigational
St. John's WortThe serum concentration of Dihydroergotamine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Dihydroergotamine can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Dihydroergotamine.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Dihydroergotamine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Dihydroergotamine.Approved
SulfisoxazoleThe metabolism of Dihydroergotamine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sulpiride.Approved
SumatriptanDihydroergotamine may increase the vasoconstricting activities of Sumatriptan.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Dihydroergotamine.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Dihydroergotamine.Approved
SynephrineDihydroergotamine may increase the hypertensive activities of Synephrine.Experimental
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Dihydroergotamine.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Dihydroergotamine.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Dihydroergotamine.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Dihydroergotamine.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Dihydroergotamine.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Dihydroergotamine.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tapentadol.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Dihydroergotamine.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Dihydroergotamine.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Dihydroergotamine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Dihydroergotamine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Dihydroergotamine.Approved
TelaprevirThe serum concentration of Dihydroergotamine can be increased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Dihydroergotamine can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Dihydroergotamine.Approved
TemocaprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Dihydroergotamine.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Dihydroergotamine.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Dihydroergotamine.Approved, Investigational, Vet Approved
TerbutalineDihydroergotamine may increase the hypertensive activities of Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Dihydroergotamine.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Dihydroergotamine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Dihydroergotamine.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Dihydroergotamine.Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thioridazine.Approved
ThiorphanThe serum concentration of Dihydroergotamine can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Dihydroergotamine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiothixene.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Dihydroergotamine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Dihydroergotamine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tiapride.Investigational
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Dihydroergotamine.Approved
TiclopidineThe metabolism of Dihydroergotamine can be decreased when combined with Ticlopidine.Approved
TimololDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Dihydroergotamine.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Dihydroergotamine.Approved
TipranavirThe serum concentration of Dihydroergotamine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineDihydroergotamine may increase the hypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Dihydroergotamine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Dihydroergotamine.Approved, Investigational
ToloxatoneThe metabolism of Dihydroergotamine can be decreased when combined with Toloxatone.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Dihydroergotamine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Dihydroergotamine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dihydroergotamine.Approved, Investigational
ToremifeneThe metabolism of Toremifene can be decreased when combined with Dihydroergotamine.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydroergotamine.Approved, Investigational
TrandolaprilThe serum concentration of Dihydroergotamine can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe metabolism of Dihydroergotamine can be decreased when combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Dihydroergotamine can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Dihydroergotamine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trazodone.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Dihydroergotamine.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Dihydroergotamine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Dihydroergotamine.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Dihydroergotamine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Dihydroergotamine.Withdrawn
TroleandomycinThe serum concentration of Dihydroergotamine can be increased when it is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Dihydroergotamine.Investigational
TulobuterolDihydroergotamine may increase the hypertensive activities of Tulobuterol.Investigational
TylosinThe serum concentration of Dihydroergotamine can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Dihydroergotamine can be increased when it is combined with Ubenimex.Experimental
UdenafilThe metabolism of Udenafil can be decreased when combined with Dihydroergotamine.Approved, Investigational
UlinastatinThe serum concentration of Dihydroergotamine can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Dihydroergotamine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Dihydroergotamine.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Dihydroergotamine.Investigational, Withdrawn
VandetanibThe metabolism of Vandetanib can be decreased when combined with Dihydroergotamine.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Dihydroergotamine.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Dihydroergotamine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Dihydroergotamine.Approved
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Dihydroergotamine.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Dihydroergotamine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Dihydroergotamine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Dihydroergotamine.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Dihydroergotamine.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Dihydroergotamine.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Dihydroergotamine.Approved
VildagliptinThe serum concentration of Dihydroergotamine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Dihydroergotamine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Dihydroergotamine.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Dihydroergotamine.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Dihydroergotamine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Dihydroergotamine.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Dihydroergotamine.Approved
VoriconazoleThe serum concentration of Dihydroergotamine can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineDihydroergotamine may increase the vasoconstricting activities of Vortioxetine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Dihydroergotamine.Approved
XimelagatranThe serum concentration of Dihydroergotamine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineDihydroergotamine may increase the hypertensive activities of Xylazine.Vet Approved
YM-178Dihydroergotamine may increase the hypertensive activities of YM-178.Investigational
Ym150The serum concentration of Dihydroergotamine can be increased when it is combined with Ym150.Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Dihydroergotamine.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Dihydroergotamine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Dihydroergotamine.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Dihydroergotamine.Approved, Illicit, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Dihydroergotamine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Dihydroergotamine.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Dihydroergotamine can be decreased when combined with Ziprasidone.Approved
ZolmitriptanDihydroergotamine may increase the vasoconstricting activities of Zolmitriptan.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Dihydroergotamine.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Dihydroergotamine.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Dihydroergotamine.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Dihydroergotamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Zotepine.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Dihydroergotamine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN02CA01N02CA51
AHFS Codes
  • 12:16.00
PDB EntriesNot Available
FDA labelDownload (412 KB)
MSDSDownload (53.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8348
Blood Brain Barrier-0.9817
Caco-2 permeable-0.7956
P-glycoprotein substrateSubstrate0.8223
P-glycoprotein inhibitor IInhibitor0.556
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterNon-inhibitor0.8229
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7227
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.895
CYP450 2D6 inhibitorNon-inhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.712
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.591
Ames testNon AMES toxic0.897
CarcinogenicityNon-carcinogens0.9549
BiodegradationNot ready biodegradable0.9961
Rat acute toxicity2.9503 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9365
hERG inhibition (predictor II)Non-inhibitor0.5788
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Valeant pharmaceuticals international
  • Bedford laboratories
  • Paddock laboratories inc
Packagers
Dosage forms
FormRouteStrength
LiquidIntramuscular; Intravenous; Subcutaneous1 mg
Injection, solutionIntramuscular; Intravenous; Subcutaneous1 mg/mL
SprayNasal4 mg/mL
LiquidNasal4 mg
Prices
Unit descriptionCostUnit
D.H.E. 45 1 mg/ml Solution 1ml Ampule124.61USD ampule
D.H.E. 45 1 mg/ml ampul120.88USD ml
Migranal 4 mg/ml Solution 1ml Glass Container94.46USD container
Migranal nasal spray90.83USD ml
D.h.e.45 1 mg/ml ampul54.46USD ml
Dihydroergotamine 1 mg/ml am38.0USD ml
Dihydroergotamine Mesylate 1 mg/ml Solution 1ml Ampule36.4USD ampule
Migranal 4 mg/ml Spray11.17USD spray
Dihydroergotamine (Dhe) 1 mg/ml4.18USD ml
Dihydroergotamine Mesylate 1 mg/ml3.9USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5169849 No1992-12-082009-12-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.229 mg/mLALOGPS
logP3.04ALOGPS
logP2.71ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)9.71ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity159.39 m3·mol-1ChemAxon
Polarizability63.3 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.9 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as ergotamines, dihydroergotamines, and derivatives. These are organic compounds containing an ergotamine moiety, which is structurally characterized by a benzyl substituent attached to the piperazine ring of the ergopeptine backbone.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassErgoline and derivatives
Sub ClassLysergic acids and derivatives
Direct ParentErgotamines, dihydroergotamines, and derivatives
Alternative Parents
Substituents
  • Ergotamine
  • Dihydroergotamine
  • Hybrid peptide
  • Lysergic acid amide
  • Indoloquinoline
  • Benzoquinoline
  • Quinoline-3-carboxamide
  • Pyrroloquinoline
  • N-acyl-alpha amino acid or derivatives
  • Quinoline
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 3-piperidinecarboxamide
  • Isoindole or derivatives
  • Indole or derivatives
  • Indole
  • Aralkylamine
  • N-alkylpiperazine
  • Benzenoid
  • Piperidine
  • Piperazine
  • Oxazolidinone
  • 1,4-diazinane
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Orthocarboxylic acid derivative
  • Lactam
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Alkanolamine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Lesage AS, Wouters R, Van Gompel P, Heylen L, Vanhoenacker P, Haegeman G, Luyten WH, Leysen JE: Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65. [PubMed:9605573 ]
  3. Buzzi MG, Moskowitz MA: The trigemino-vascular system and migraine. Pathol Biol (Paris). 1992 Apr;40(4):313-7. [PubMed:1379707 ]
  4. Buzzi MG, Dimitriadou V, Theoharides TC, Moskowitz MA: 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation. Brain Res. 1992 Jun 26;583(1-2):137-49. [PubMed:1324091 ]
  5. Silberstein SD, McCrory DC: Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb;43(2):144-66. [PubMed:12558771 ]
  6. Hoyer D, Lery H, Waeber C, Bruinvels AT, Nozulak J, Palacios JM: "5-HT1R" or 5-HT1D sites? Evidence for 5-HT1D binding sites in rabbit brain. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):249-54. [PubMed:1407010 ]
  7. Villalon CM, Centurion D, Willems EW, Arulmani U, Saxena PR, Valdivia LF: 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol. 2004 Jan 26;484(2-3):287-90. [PubMed:14744615 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Willems EW, Trion M, De Vries P, Heiligers JP, Villalon CM, Saxena PR: Pharmacological evidence that alpha1-and alpha2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Br J Pharmacol. 1999 Jul;127(5):1263-71. [PubMed:10455274 ]
  2. Villalon CM, Centurion D, Willems EW, Arulmani U, Saxena PR, Valdivia LF: 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol. 2004 Jan 26;484(2-3):287-90. [PubMed:14744615 ]
  3. Buzzi MG, Moskowitz MA: Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia. 1991 Sep;11(4):165-8. [PubMed:1660351 ]
  4. Yu XJ, Waeber C, Castanon N, Scearce K, Hen R, Macor JE, Chauveau J, Moskowitz MA: 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors. Mol Pharmacol. 1996 May;49(5):761-5. [PubMed:8622623 ]
  5. Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC: Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state. Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9. [PubMed:9650800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Villalon CM, Centurion D, Willems EW, Arulmani U, Saxena PR, Valdivia LF: 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol. 2004 Jan 26;484(2-3):287-90. [PubMed:14744615 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L: Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol. 2003 Sep;140(2):277-84. Epub 2003 Aug 11. [PubMed:12970106 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  2. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23